| Market Cap | 2B 1.74B 1.6B 1.5B 2.8B 192B 2.86B 19.09B 7.39B 92.33B 7.51B 7.35B 321B | P/E Ratio 2026 * |
-6.53x | P/E Ratio 2027 * | -5.35x |
|---|---|---|---|---|---|
| Enterprise Value | 2B 1.74B 1.6B 1.5B 2.8B 192B 2.86B 19.09B 7.39B 92.33B 7.51B 7.35B 321B | EV / Sales 2026 * |
48.5x | EV / Sales 2027 * | 54.2x |
| Free-Float |
99.55% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nektar Therapeutics
| 1 day | -0.71% |
| Manager | Title | Age | Since |
|---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 73 | 2006-12-31 |
Linda Rubinstein
DFI | Director of Finance/CFO | 60 | 2026-05-14 |
| Chief Tech/Sci/R&D Officer | 52 | 2015-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Roy Whitfield
BRD | Director/Board Member | 72 | 2000-07-31 |
Robert Chess
CHM | Chairman | 67 | 1992-04-30 |
Howard Robin
BRD | Director/Board Member | 73 | 2007-01-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | +1.97% | - | - | 2B | |
| +1.65% | +6.42% | +53.16% | +112.78% | 55.58B | |
| +0.03% | +0.33% | +49.22% | +43.94% | 43.47B | |
| +3.93% | -0.06% | -15.10% | -18.04% | 22.64B | |
| +5.27% | -7.82% | -1.29% | +388.48% | 20.96B | |
| +3.07% | -5.86% | +11.06% | -30.11% | 15.79B | |
| +0.53% | +2.08% | +8.89% | -39.59% | 15.3B | |
| +1.75% | +1.92% | +29.13% | +178.65% | 13.45B | |
| +8.77% | +8.80% | +17.78% | - | 11.74B | |
| -5.27% | -0.43% | +87.77% | +208.02% | 10.96B | |
| Average | +1.86% | -0.42% | +26.74% | +105.52% | 23.32B | |
| Weighted average by Cap. | +1.94% | +0.76% | +31.44% | +98.49% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 41.22M 35.77M 32.97M 30.89M 57.72M 3.95B 58.93M 393M 152M 1.9B 155M 151M 6.61B | 36.91M 32.03M 29.52M 27.66M 51.68M 3.53B 52.76M 352M 136M 1.7B 139M 136M 5.92B |
| Net income | -250M -217M -200M -187M -350M -23.94B -357M -2.39B -924M -11.54B -939M -918M -40.13B | -356M -309M -285M -267M -498M -34.07B -509M -3.39B -1.31B -16.42B -1.34B -1.31B -57.1B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
